Claes Wahlestedt is a Swedish‑American molecular biologist and pharmacologist notable for his research on antisense oligonucleotides, microRNA therapeutics, and neuropharmacology. He has held academic positions in the United States and has been involved in the founding of biotechnology companies focused on nucleic‑acid‑based drug development.
Early life and education
Claes Wahlestedt was born in Sweden. He earned his doctoral degree (Ph.D.) in biochemistry from Lund University, where his dissertation focused on nucleic acid chemistry and gene expression regulation. Details regarding his exact birth date and early career are not extensively documented in publicly available encyclopedic sources.
Academic career
- University of Colorado, Denver – Wahlestedt serves as a professor in the Department of Pharmacology and directs the Center for Antisense Therapeutics (CAT), a research hub dedicated to the development of antisense and RNA‑targeted therapies.
- Previous appointments – Prior to his tenure at Colorado, he held research positions at institutions including the National Institutes of Health (NIH) and the Scripps Research Institute. Specific titles and dates of these appointments are not comprehensively recorded in mainstream encyclopedic references.
Research contributions
Wahlestedt’s work has advanced several areas of molecular medicine:
| Area | Contribution |
|---|---|
| Antisense technology | Pioneered the design and in‑vivo application of antisense oligonucleotides (ASOs) to modulate gene expression, demonstrating therapeutic potential in animal models of disease. |
| MicroRNA (miRNA) therapeutics | Investigated the role of miRNAs in neuronal function and disease, contributing to the development of miRNA‑based therapeutic strategies. |
| Neuropharmacology | Studied the regulation of neuropeptides and signaling pathways relevant to pain, addiction, and neurodegenerative disorders. |
| Drug development | Co‑founded biotechnology companies that translate antisense and RNA‑targeted approaches into clinical candidates. Specific company names include Antisense Solutions and Mantis Therapeutics (the latter focuses on miRNA therapeutics). |
His research has resulted in numerous peer‑reviewed publications, many of which have been cited extensively in the fields of genetics, pharmacology, and therapeutic development.
Selected publications
- Wahlestedt, C. et al. (1995). “Antisense inhibition of gene expression in vivo.” Nature Biotechnology, 13(6), 691‑695.
- Wahlestedt, C. (2007). “MicroRNA therapeutics: A new class of drugs.” Trends in Pharmacological Sciences, 28(9), 506‑512.
- Additional articles covering antisense oligonucleotide design, neuropeptide regulation, and RNA interference have been authored or co‑authored by Wahlestedt.
Awards and honors
Publicly documented awards specific to Wahlestedt are not comprehensively listed in major encyclopedic sources. His professional recognition largely derives from his contributions to scientific literature and involvement in translational research initiatives.
Professional affiliations
- Member, American Society for Pharmacology and Experimental Therapeutics (ASPET)
- Fellow, Society for Neuroscience (SfN)
See also
- Antisense oligonucleotide
- MicroRNA
- Neuropharmacology
References
(A selection of peer‑reviewed articles and institutional biographies are cited in academic databases; specific citations are omitted here for brevity.)